Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2009

01-12-2009 | Healthcare Policy and Outcomes

Outcome of Low-Volume Surgery for Esophageal Cancer in a High-Volume Referral Center

Authors: Ewout F. W. Courrech Staal, MD, Frits van Coevorden, MD, PhD, Annemieke Cats, MD, PhD, Berthe M. P. Aleman, MD, PhD, Marie-Louise F. van Velthuysen, MD, PhD, Henk Boot, MD, PhD, Marie-Jeanne T. F. D. Vrancken Peeters, MD, PhD, Johanna W. van Sandick, MD, PhD

Published in: Annals of Surgical Oncology | Issue 12/2009

Login to get access

Abstract

Background

There is a known inverse relationship between the number of esophagectomies and in-hospital mortality. Our institute is a tertiary referral center with a high caseload of esophageal cancer patients, but with a low annual volume of esophagectomies. The objective of our study was to evaluate the results of esophageal cancer surgery in our institute and to compare these results with published data from high-surgical-volume institutions.

Methods

Between 1995 and 2007, 1,499 patients with esophageal cancer were referred: for a second opinion only (n = 568), following earlier treatment (n = 103), for palliative treatment (n = 665) or for potentially curative treatment (local endoscopic therapy n = 5, definitive chemoradiotherapy n = 71, or surgery n = 87). The surgically treated patients were studied in detail, and compared with patients treated in high-surgical-volume hospitals.

Results

Surgery consisted of a transhiatal (n = 71) or transthoracic (n = 12) esophagectomy, or exploration only (n = 4). Fifty-six (64%) patients received neoadjuvant treatment. A microscopic radical resection was achieved in 96%. Pathologic complete response rate was 25%. Forty-four (53%) patients had a complicated postoperative course, and one (1%) patient died. At a median postoperative follow-up of 30 (1–149) months, 1- and 3-year overall survival rates were 89% and 60%, respectively. No major differences were observed between our results and those presented in six large study cohorts with high operative volumes.

Conclusions

Outcome of low-volume esophageal surgery can be comparable to published high-surgical-volume results. More relevant factors other than hospital volume alone should be taken into account to improve outcome of esophageal cancer surgery.
Literature
1.
Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg. 2001;72:306–13.CrossRefPubMed
2.
Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37(Suppl 8):S4–66.CrossRefPubMed
3.
Visser OCJ, Schouten LJ, van Dijk JAAM. Incidence of cancer in the Netherlands 1997. Vereniging van Integrale Kankercentra: Utrecht; 2001.
4.
Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–34.CrossRefPubMed
5.
Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349:2117–27.CrossRefPubMed
6.
Killeen SD, O’Sullivan MJ, Coffey JC, Kirwan WO, Redmond HP. Provider volume and outcomes for oncological procedures. Br J Surg. 2005;92:389–402.CrossRefPubMed
7.
Chowdhury MM, Dagash H, Pierro A. A systematic review of the impact of volume of surgery and specialization on patient outcome. Br J Surg. 2007;94:145–61.CrossRefPubMed
8.
Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 1993;11:1118–23.PubMed
9.
Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.CrossRefPubMed
10.
Al Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997;15:277–84.PubMed
11.
Polee MB, Sparreboom A, Eskens FA, et al. A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. Clin Cancer Res. 2004;10:1928–34.CrossRefPubMed
12.
El Rayes BF, Shields A, Zalupski M, et al. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol 2004;15:960–5.CrossRefPubMed
13.
Wang H, Ryu J, Gandara D, et al. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol. 2007;2:153–7.CrossRefPubMed
14.
Bamias A, Hill ME, Cunningham D, et al. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. Cancer. 1996;77:1978–85.CrossRefPubMed
15.
Evans TR, Pentheroudakis G, Paul J, et al. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Ann Oncol. 2002;13:1469–78.CrossRefPubMed
16.
Sobin LH, Wittekind C. TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss; 2002.
17.
Orringer MB, Marshall B, Chang AC, Lee J, Pickens A, Lau CL. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg. 2007;246:363–72.CrossRefPubMed
18.
Lagarde SM, de Boer JD, Ten Kate FJ, Busch OR, Obertop H, van Lanschot JJ. Postoperative complications after esophagectomy for adenocarcinoma of the esophagus are related to timing of death due to recurrence. Ann Surg. 2008;247:71–6.CrossRefPubMed
19.
Wouters MW, Wijnhoven BP, Karim-Kos HE, et al. High-volume versus low-volume for esophageal resections for cancer: the essential role of case-mix adjustments based on clinical data. Ann Surg Oncol. 2008;15:80–7.CrossRefPubMed
20.
Davies AR, Forshaw MJ, Khan AA, Noorani AS, Patel VM, Strauss DC, et al. Transhiatal esophagectomy in a high volume institution. World J Surg Oncol. 2008;6:88.CrossRefPubMed
21.
Rutegard M, Lagergren J, Rouvelas I, Lagergren P. Surgeon volume is a poor proxy for skill in esophageal cancer surgery. Ann Surg. 2009;249:256–61.CrossRefPubMed
22.
Ruol A, Castoro C, Portale G, et al. Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution. Arch Surg. 2009;144:247–54.CrossRefPubMed
23.
Lagarde SM, Reitsma JB, Maris AK, et al. Preoperative prediction of the occurrence and severity of complications after esophagectomy for cancer with use of a nomogram. Ann Thorac Surg. 2008;85:1938–45.CrossRefPubMed
24.
25.
Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305–13.PubMed
26.
Nieveen van Dijkum EJ, de Wit LT, van Delden OM, Rauws EA, van Lanschot JJ, Obertop H, et al. The efficacy of laparoscopic staging in patients with upper gastrointestinal tumors. Cancer. 1997;79:1315–9.CrossRefPubMed
27.
van Lanschot JJ, Hulscher JB, Buskens CJ, Tilanus HW, Ten Kate FJ, Obertop H. Hospital volume and hospital mortality for esophagectomy. Cancer. 2001;91:1574–8.CrossRefPubMed
28.
Rodgers M, Jobe BA, O’Rourke RW, Sheppard B, Diggs B, Hunter JG. Case volume as a predictor of inpatient mortality after esophagectomy. Arch Surg. 2007;142:829–39.CrossRefPubMed
29.
Urbach DR, Baxter NN. Does it matter what a hospital is “high volume” for? Specificity of hospital volume-outcome associations for surgical procedures: analysis of administrative data. BMJ. 2004;328:737–40.CrossRefPubMed
Metadata
Title
Outcome of Low-Volume Surgery for Esophageal Cancer in a High-Volume Referral Center
Authors
Ewout F. W. Courrech Staal, MD
Frits van Coevorden, MD, PhD
Annemieke Cats, MD, PhD
Berthe M. P. Aleman, MD, PhD
Marie-Louise F. van Velthuysen, MD, PhD
Henk Boot, MD, PhD
Marie-Jeanne T. F. D. Vrancken Peeters, MD, PhD
Johanna W. van Sandick, MD, PhD
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0700-5

Other articles of this Issue 12/2009

Annals of Surgical Oncology 12/2009 Go to the issue

Colorectal Cancer

Notch2 Expression Is Decreased in Colorectal Cancer and Related to Tumor Differentiation Status

Gastrointestinal Oncology

Peritoneal Dissemination: A Pending Issue in Gastric Cancer Worth Exploring

Colorectal Cancer

Extended Lymph Node Dissection for Rectal Cancer with Radiologically Diagnosed Extramesenteric Lymph Node Metastasis

Breast Oncology

Risk Factors Associated with Conversion from Nonmalignant to Malignant Diagnosis After Surgical Excision of Breast Papillary Lesions

Breast Oncology

Can Axillary Lymph Node Dissection Be Safely Omitted for Early-Stage Breast Cancer Patients with Sentinel Lymph Node Micrometastasis?

Pancreatic Tumors

Survival Data Justifies Resection for Pancreatic Metastases